
Blue Line Capital

Corporate Trends Ahead Of CPI Pharma, Streaming & Semiconductors

Economic Dynamics Housing, Inflation & More


Credit Spread

Investment grade one grade above junk (Baa) finds itself less than 100bps above Fed Funds, indicating a lack of stress in credit.



House Prices & Construction Activity

House prices have been extremely resilient despite the 30-year fixed mortgage rate rising from ~2.6% in Jan. 2021 to a high of ~7% in Oct. 2022.



Sources: FRED, Blue Line Capital, Blue Line Futures


Housing construction activity strong after underbuilding post-GFC.






Vacancy Rates

According to Moody's, today's vacancy rate indicates the U.S. is short 1.5 years of housing supply.




Sources: FRED, Blue Line Capital, Blue Line Futures

Rental vacancy as low as it's last been in the 1980s.



Mortgage Applications & Buyer Sentiment


Despite higher mortgage rates, home buyers have been reluctant to retreat.



Sources: MBA, Fannie Mae, Blue Line Capital, Blue Line Futures

Buyer sentiment has come off significantly.

Only 17% of consumers say it's a good time to buy a home




Source: Home Purchase Sentiment Index® (HPSI)




GDP & Leading Economic Indicator

GDP growth has been extraordinarily resilient as consumers have kept spending, proving resilient in response to higher rates.




Sources: Atlanta Fed, FRED, Blue Line Capital, Blue Line Futures

Leading economic indicators have collapsed across the board (as of Dec.)




Wage Trends

12-month moving average of average hourly earnings.



Workers' share of corporate income



Sources: Atlanta Fed, Economic Policy Institute, Blue Line Capital, Blue Line Futures

Employee Count By Occupation

Employee count by occupation 2019 - 2022

	2022	2021	2020	2019	Δ (2022-2019)	∆/2019
Management occupations	20199	18986	18564	18985	1214	6%
Business and financial operations occupations	9152	8878	8578	7996	1156	14%
Professional and related occupations	38749	36880	36502	37237	1512	4%
Architecture and engineering occupations	3464	3235	3169	3305	159	5%
Life, physical, and social science occupations	1840	1640	1627	1485	355	24%
Community and social service occupations	2945	2777	2717	2717	228	8%
Legal occupations	1861	1805	1882	1955	-94	-5%
Education, training, and library occupations	9220	8946	8902	9455	-235	-2%
Arts, design, entertainment, sports, and media occupations	3441	3151	3042	3285	156	5%
Healthcare practitioners and technical occupations	9808	9639	9559	9684	124	1%
Healthcare support occupations	4930	4887	4790	3758	1172	31%
Protective service occupations	3057	2987	3024	3128	-71	-2%
Food preparation and serving related occupations	7907	7370	6556	8378	-471	-6%
Supervisors of personal care and service workers	232	250	237	213	19	9%
Sales and related occupations	14316	14369	14168	15582	-1266	-8%
Office and administrative support occupations	16096	15797	15558	17789	-1693	-10%
Farming, fishing, and forestry occupations	980	1061	1045	1156	-176	-15%
Construction and extraction occupations	8427	8057	7710	8325	102	1%
Installation, maintenance, and repair occupations	4853	4840	4602	4862	-9	0%
Production occupations	8256	7950	7590	8565	-309	-4%
Transportation and material moving occupations	11826	11359	10625	10063	1763	18%

Sources: BLS, Blue Line Capital, Blue Line Futures

Earnings Data & Corporate Trends

AbbVie, Disney, Intel

AbbVie **Product Differentiation Post Humira**

AbbVie Earnings Highlights & Stock Performance


Management Commentary From Q4 2022 Earnings Call

- <u>Skyrizi and Rinvoq:</u> We anticipate these two products will collectively exceed the peak revenues achieved by HUMIRA by 2027 with significant growth expected through the end of the decade.
- <u>R&D</u>: We are committed to pursuing new ways to address patients' most serious health issues and have more than doubled our annual R&D investment since our inception. The breadth and the depth of our pipeline, which now includes more than 80 programs across all development stages.
- <u>Humira:</u> We expected headwind from direct biosimilar competition with U.S. HUMIRA sales down approximately 37%, which is at lower end of our previous erosion projection of 35% to 55%.
- <u>Debt:</u> We expect to pay down \$4bn in maturities this year bringing our cumulative debt reduction to \$34bn.

	P/E	P/S	M	/В		
NTM	12	.82	4.84	12.59	12.03	NA
TTM	22.	.43	4.53	13.06	10.33	16.44
*Levered FCF						


Sources: AbbVie IR, TIKR, Blue Line Capital

Quarterly Data



The AbbVie Portfolio & Pipeline

The AbbVie Portfolio & Pipeline (From Allergan Acquisition)




Sources: AbbVie IR, Blue Line Capital

6000

The AbbVie Portfolio | Q3 vs. Q4 Sales By Product


The AbbVie Portfolio & Trends




Sources: AbbVie IR, Blue Line Capital

6000

Humira Patent Loss




Humira Global Sales Projections (FactSet)




Replacing Humira Sales

Revenue By Segment



Sources: AbbVie IR, Statista, Blue Line Capital

IBD Disease Projections (Includes Crohn's Diseases)



AbbVie Expectations & Returns

Return Ratios Compared To 2019

Return and profit ratios have remained stable across the board.

		LTM	2019
Return	RoA	9.30%	12.00%
Return	RoC	26.40%	23.70%
Ratios	RoE	75.30%	-94.90%
	Gross Profit Margin	71.50%	77.60%
Margins	EBITDA Margin	53.50%	48.90%
Margiris	Net Income Margin	20.40%	23.70%
	Levered Free Cash Flow Margin	34.90%	26.30%
	Asset Turnover	0.41	0.37
Asset	Fixed Asset Turnover	11.54	10.75
Turnover	Receivables Turnover	5.77	61.5
	Inventory Turnover	5.57	4.35
	Total Debt/Equity	436.80%	-821.90%
Calvanav	Total Debt/Capital	81.40%	111.70%
Solvency	EBITDA/Interest Expense	15.21	9.24
	(EBITDA/Capex)/Interest Expense	15.21	8.93

Sources: AbbVie IR, TIKR, Blue Line Capital

Revenue and Net Income Estimates



AbbVie Valuation Vs. Peers

	EV/EBITDA	NTM P/E	Past 3M Return	Past 6m Return	Past 12m Return
AbbVie (ABV)	12.69	13.59	-4%	2%	-7%
Amgen (AMGN)	10.0	13.58	-16%	-4%	-2%
Gilead (GILD)	7.5	12.66	6%	5%	3%
Regeneron (REGN)	11.6	18.26	2%	17%	12%
Merck (MRK)	11.96	15.13	9%	18%	15%
Johnson & Johnson (JNJ)	12.16	15.43	-3%	-1%	-9%
Bristol-Myers Squibb					
(BMY)	9.32	9.02	-3%	-1%	-6%
Median	11.60	13.59	-3%	2%	-2%
Mean	10.75	13.95	-1%	5%	1%



Disney Earnings Highlights & Stock Performance

Management Commentary From Q1 2023 Earnings Call

- <u>Cost Savings:</u> Targeting \$5.5bn of cost savings across the company. We will be reducing our workforce by approximately 7,000 jobs.
- <u>Priorities:</u> Instead, our priority is the enduring growth and profitability of our streaming business. Our current forecasts indicate Disney+ will hit profitability by the end of fiscal 2024, and achieving that remains our goal.
- <u>Disney+</u>: The Disney+ domestic price increase has been playing out as expected, with only modestly higher churn, which may also negatively impact the fiscal second quarter given the timing of the December price increase.
- <u>Succession Planning:</u> And finally, on the topic of succession, the Board recently established a dedicated Succession Planning Committee.
- <u>Cash Content Spend</u>: We still expect cash content spend company-wide to remain in the low \$30bn range for fiscal 2023.

	P/E	P/S	Market Cap/FCF EV/EBITDA P/B			
NTM	24.	38	2.2	46.9	15.89	NA
TTM	60.	64 2	.39	41.52	21.37	2.1
*Levered FCF	=					


Sources: Disney IR, TIKR, Blue Line Capital

Quarterly Data



Disney – DTC Subscribers & Disney+

Total Disney Direct-to-Consumer Subscriber Count




Sources: Disney IR, Blue Line Capital

Disney+ Subscribers & ARPU



Disney - ESPN+ & Hulu

ESPN+ Subscriber Count & ARPU




Sources: Disney IR, Blue Line Capital

Hulu Subscriber Count & ARPU




Parks & Others vs. Media | Sales & Operating Income

Media & Park Revenues (Including Q1 Run-Rate)




Sources: Disney IR, Blue Line Capital

Media & Parks Operating Income (Including Q1 Run-Rate)




Disney - The Transition From Linear To Streaming

Linear vs. Streaming Revenue




Sources: Disney IR, Blue Line Capital

Linear vs. Streaming Operating Income



Disney Content Spend Trends

Disney Direct-To-Consumer Content Spend




Sources: Disney IR, McKinsey, Marketing Charts, Blue Line Capital

Streaming Spend & Shift From Linear Advertising

- According to Marketing Charts, 60% of surveyed participants did stream or download TV while 73% of participants watched linear TV. In 2021, 77% of people indicated they streamed and 61% indicated they watched linear TV.
- A study by McKinsey indicates that television (linear TV) will only account for 23.1% of global ad spend in 2024 (down from 29% in 2019).





Source: McKinsey & Company, Wilkofsky Gruen Associates



Disney Expectations & Returns


Return Ratios Compared To 2019

In the transition to DTC, Disney's return metrics have suffered across the board.

		LTM	2019
Return	RoA	2.10%	5.10%
Return	RoC	4.00%	7.60%
Ratios	RoE	3.50%	13.90%
	Gross Profit Margin	33.40%	39.60%
Margina	EBITDA Margin	14.10%	23.30%
Margins	Net Income Margin	3.90%	15.90%
	Levered Free Cash Flow Margin	5.80%	7.30%
	Asset Turnover	0.42	0.36
Asset	Fixed Asset Turnover	2.52	2.28
Turnover	Receivables Turnover	5.85	6.74
	Working Capital Turnover	-534.27	-21.64
	Total Debt/Equity	44.40%	45.80%
Solvency	Total Debt/Capital	29.20%	29.90%
	EBITDA/Interest Expense	7.9	13
	(EBITDA/Capex)/Interest Expense	4.79	9.09

Sources: Disney IR, TIKR, Blue Line Capital

Revenue, Net Income, and FCF Estimates



Disney Valuation Vs. Peers

	EV/EBITDA	NTM P/E	Past 3M Return	Past 6m Return	Past 12m Return
Disney (DIS)	15.62	24.03	18%	-10%	3%
Netflix (NFLX)	21.9	30.44	26%	47%	93%
Warner Bros Discovery					
(WBD)	8.3	-61.13	23%	11%	-21%
Fox Corp (FOXA)	7.83	11.25	16%	-2%	2%
Charter Communications					
(CHTR)	7.36	11.56	2%	-16%	-15%
Comcast (CMCSA)	7.31	10.52	14%	-4%	-10%
Paramount (PARA)	10.8	16.71	19%	-16%	-31%
Median	8.30	11.56	18%	-4%	-10%
Mean	11.30	6.20	17%	1%	3%



Intel Earnings Highlights & Stock Performance

Management Commentary From Q4 2022 Earnings Call

- <u>PC:</u> In Q3, we provided an estimate for the calendar year '23 PC consumption TAM of 270 million to 295 million units. Given continued uncertainty and demand signals we see in Q1, we expect the lower end of that range is more likely outcome. Near term, the PC ecosystem continues to deplete inventory.
- <u>Server:</u> We expect Q1 server consumption TAM to decline both sequentially and year-over-year at an accelerated rate with first half'23 server consumption TAM down year-on-year before returning to growth in the second half.
- <u>Foundry Cost Cuts:</u> We expect additional efficiencies as we implement our internal foundry model, which is a key element to accomplish our \$8bn to \$10bn of cost savings exiting 2025.

	P/E	P/S	Market Cap/FCF EV/EBITDA P/B			
NTM	52	2.07	2.26	-14.13	12.67	NA
TTM	74	4 .29	1.82	26.7	8.42	1.13
*Levered FCI	=					


Sources: Intel IR, TIKR, Blue Line Capital

Quarterly Data



Intel Quarterly Revenues & Income Trends

Revenue By Segment



Sources: Intel IR, Blue Line Capital

Quarterly Revenue Trends

	Q4 2022	Q4 2021	%
Desktop	2509	3756	-33%
Notebook	3663	5809	-37%
Other	453	738	-39%
Data Center and Al	4304	6426	-33%
Network and Edge	2061	2086	-1%
Mobileye	565	356	59%
Accelerated Computing Systems and Graphics	247	245	1%
Intel Foundry Services	319	245	30%
All other	30	1033	-97%


Quarterly Operating Income Trends

	Q4 2022	Q4 2021	%
Client Computing	699	3795	-82%
Data Center and Al	371	2350	-84%
Network and Edge	58	352	-84%
Mobileye	210	123	71%
Accelerated Computing Systems	2.71	671	31%
and Graphics	-441	-641	31%
Intel Foundry Services	-31	3	-1133%
All other	-1998	-993	-101%




Intel Annual Revenue & Income Trends

Revenue By Segment



Sources: Intel IR, Blue Line Capital


Operating Income(Loss) By Segment





Intel Annual Revenue Trend

Revenue By Segment




Sources: Intel IR, Blue Line Capital

Intel – Geographic Exposure & Notebook, PC Trends

Sales By Geography






Sources: Intel IR, Statista, Blue Line Capital

Intel In Too Many Places

 Given that Intel both competed with and manufactured for competitors, the company had to keep spending on foundry technology while falling behind TSMC and Samsung.



2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

Intel Expectations & Returns


Return Ratios Compared To 2019

Intel has disappointed across metrics.

		LTM	2019
Return	RoA	0.80%	10.60%
Return	RoC	1.60%	20.70%
Ratios	RoE	8.10%	27.70%
	Gross Profit Margin	42.60%	58.60%
Margine	EBITDA Margin	24.40%	46.20%
Margins	Net Income Margin	12.70%	29.20%
	Levered Free Cash Flow Margin	6.80%	17.00%
	Asset Turnover	0.35	0.53
Asset	Fixed Asset Turnover	0.87	1.38
Turnover	Receivables Turnover	9.28	10.01
	Inventory Turnover	3.02	3.73
	Total Debt/Equity	41.40%	37.50%
Solvency	Total Debt/Capital	29.10%	26.80%
	EBITDA/Interest Expense	32.46	68
	(EBITDA-Capex)/Interest Expense	-18.04	34.85

Sources: Intel IR, TIKR, Blue Line Capital

Revenue, Net Income, and FCF Estimates



Intel Vs. Peers

	EV/EBITDA	NTM P/E	Past 3M Return	Past 6m Return	Past 12m Return
Intel (INTC)	12.69	51.39	-7%	-22%	-36%
NVIDIA (NVDA)	59.24	54.99	36%	17%	22%
Taiwan Semicond. (TSM)	8.58	16.16	28%	3%	1%
Broadcom (AVGO)	12.39	14.55	16%	8%	-1%
Qualcomm (QCOM)	10	12.81	9%	-13%	-5%
AMD (AMD)	16.42	26.74	17%	-16%	-17%
Micron (MU)	12	-30.15	-4%	-7%	-19%
Median	12.39	16.16	16%	-7%	-5%
Mean	18.76	20.93	14%	-4%	-8%

Data Disclosures

Performance, portfolio, sector and holdings data is provided by Morningstar. (c) Morningstar 2022. All rights reserved. Use of this content requires expert knowledge. It is to be used by specialist institutions only. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied, adapted or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information, except where such damages or losses cannot be limited or excluded by law in your jurisdiction. Past financial performance is no guarantee of future results.

General Disclosures

The information contained in this document pertains to Blue Line Capital, LLC ("BLC"). All rights are reserved. These materials are the sole property of BLC. The information supplied herein is proprietary and confidential and is intended only for the persons to whom it is transmitted. Receipt or possession of this document does not convey any rights to disclose its contents, in whole or in part, to any third party, or to develop, manufacture, use, or sell anything described herein.